All rights reserved.. Moscow Times Examines Russia’s First Full-Service Health Center For Sex WorkersMoscow Times on Monday examined Simona – Russia’s first full-service health center, free medical, legal and psychological services for commercial sex workers. – – located in the Republic of Tatarstan, Russia – is ‘new territory’in the country in the fight against HIV / AIDS and is aimed at no-cost HIV testing and HIV prevention training for sex workers offer, the New York Times reports. Doctors at the clinic ‘, like they did with regular patients, but with an eye toward promoting safe behavior,’Yulia Kuznetsova – an administrator at the AIDS Information Share , who runs the hospital – said. Since its opening since its opening at the beginning of 150 people who have visited 252 times and has distributed more than 11,800 condoms, seen by the Times.
Dr. Said the hospital now plans of of RapidArc treatments to other pelvic tumors and head and neck cancers include. PYNEH is one of six public cancer centers in Hong Kong.‘But the governor of also announced that Nebraska is looking for a $ 1,000 federal subsidy for a health insurance exchange’ that we plan.. In the meantime the condition followed by Nebraska helping a $ 1,000 contribution, $ 1 thousand a health insurance exchange of as a part of Reconditioning, which Omaha World-Herald reported to Nebraska ‘Gouverneur Dave Heineman back blended political to pragmatism about the Germany healthcare reform Wednesday during form wrestling guides through a point on the legislation. Heineman radiated the law of in a a letter urging a group of senators to call for their removal. In now-familiar language, he said law ‘raise taxes in Nebraskans, sections of Medicaid and caused health insurance premiums increasing.
September 2009 , the company has Subminiature – licensed its Onalta brand 90 – Y is edotreotide radiotherapeutic in some countries into Europe, the Middle East, North Africa, Russia and Turkey BioMedica Life Sciences in, SA The European Medicines Agency for has reviewed and Onalta Phase 3 accept clinical trial protocol design and have Onalta granted Orphan Drug Designation provided. Molecular Insight retains all rights Onalta in all other markets and regions including which USA, Japan and Asia. Onalta did also Already a drug program Drug status by the U.S. Food and Drug Administration.. Molecular Insight license rights to edotreotide by Novartis Pharma Ltd.